A New Way Out of the Predicament of Anaplastic Thyroid Carcinoma From Existing Data Analysis
BackgroundAnaplastic thyroid carcinoma (ATC) is an endocrine tumor with a low incidence but a very poor prognosis. The vast majority of patients have a survival time of only three to six months, but a few survive for two years or more. In recent years, there have been major breakthroughs in targeted...
Main Authors: | Yikun Zhou, Yang Zhao, Xi Ding, Jing Liang, Huayang Xu, Yuxuan Lin, Hamad Haider Khan, Bingyin Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-05-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.887906/full |
Similar Items
-
Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years
by: Julia Jacob, et al.
Published: (2023-04-01) -
Hypofractionated Radiotherapy for Anaplastic Thyroid Cancer: Systematic Review and Pooled Analysis
by: Dmytro Oliinyk, et al.
Published: (2020-09-01) -
Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients
by: Teresa Augustin, et al.
Published: (2020-10-01) -
Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management
by: Jiaqian Yuan, et al.
Published: (2022-12-01) -
MiR-155 promotes anaplastic thyroid cancer progression by directly targeting SOCS1
by: Wei Zhang, et al.
Published: (2019-11-01)